Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters








Language
Year range
1.
National Journal of Andrology ; (12): 775-781, 2015.
Article in Chinese | WPRIM | ID: wpr-276021

ABSTRACT

<p><b>OBJECTIVE</b>To investigate the expression of the Pim-1 gene in the LNCaP cells of the animal model of orthotopically implanted prostate cancer by surgical castration simulating androgen-deprivation therapy.</p><p><b>METHODS</b>We equally allocated 32 male BALBc-nu mice into 4 groups, androgen-dependent prostate cancer (ADPC), androgen-deprivation therapy (ADT) , castration-resistant prostate cancer (CRPC) and blank control, and established the models of orthotopically implanted tumor using human prostate cancer LNCaP cells. We detected and ,compared the expressions of Pim-1, PSA, and androgen receptor (AR) in the tumor tissues of different groups by RT-PCR. qRT-PCR, ELSIA and immunohistochemistry.</p><p><b>RESULTS</b>The relative gray scales in the ADPC and CRPC groups were 0.59 ± 0.01 and 1.14 ± 0.02, with statistically significant differences from 0.62 ± 0.03 in the ADT group (P < 0.05), and the Δ Ct values of Pim-1 were 6.15 ± 0.34 and 4.56 ± 0.23 in the former two groups, also with significant differences from 5.11 ± 0.21 in the latter (P < 0.05). The results of 2-ΔΔ Ct relative quantification analysis showed that the amplification products of Pim-1 in the ADT and CRPC groups increased 2.05 and 3.01 times respectively that of the ADPC group. The concentration of PSA was significantly higher in the ADPC ([480 ± 25] pg/ml) and CRPC ([870 ± 23] pg/ml) than in the ADT ([170 ± 32] pg/ml) and blank control groups (0 µg/L) (P < 0.01). The mean optical densities of Pim-1 and AR proteins were 0.017 ± 0.002 and 0.032 ± 0.009 in the ADPC group and 0.024 ± 0.002 and 0.040 ± 0.011 in the CRPC group, both with significant differences from those in the ADT group (0.018 ± 0.001 and 0.019 ± 0.006) (P < 0.01).</p><p><b>CONCLUSION</b>Pim-1 is highly expressed in nude mice with prostate cancer receiving androgen-deprivation therapy and plays an important role in the progression and metastasis of prostate cancer.</p>


Subject(s)
Animals , Humans , Male , Mice , Androgen Antagonists , Therapeutic Uses , Disease Progression , Gene Expression , Heterografts , Mice, Inbred BALB C , Mice, Nude , Neoplasms, Hormone-Dependent , Metabolism , Prostate-Specific Antigen , Metabolism , Prostatic Neoplasms, Castration-Resistant , Genetics , Metabolism , Therapeutics , Proto-Oncogene Proteins c-pim-1 , Metabolism , Receptors, Androgen , Metabolism
2.
National Journal of Andrology ; (12): 825-828, 2011.
Article in Chinese | WPRIM | ID: wpr-305781

ABSTRACT

<p><b>OBJECTIVE</b>To study the clinical manifestations, pathological characteristics and treatment methods of prostate cancer with five different histological features.</p><p><b>METHODS</b>We reported 1 case of prostate cancer with five different histological features and further analyzed the diagnosis, pathology and treatment of the disease by reviewing the relevant literature.</p><p><b>RESULTS</b>The patient was an 84-year-old male, admitted due to difficult urination and dribbling urine for 1 year, hematuria for 8 months and deterioration for 2 weeks. Prostate cancer was indicated by rectal examination, ultrasonography, CT, MRI and PSA, and confirmed by biopsy. Considering the general condition of the patient, we performed electrotransurethral resection under epidural anesthesia to alleviate his urinary symptoms and remove suspected tumor tissues. Postoperative pathology showed the case to be prostate adenocarcinoma, histologically characterized by cribriform carcinoma, acinar carcinoma, diffuse invasive carcinoma, ductal carcinoma, and mucinous adenocarcinoma, with a Gleason score of 9. Bicalutamide and goserelin were administered postoperatively. Systemic metastasis occurred 10 months later, and the patient died 1 year after the operation.</p><p><b>CONCLUSION</b>Prostate cancer with five different histological features is extremely rare. Its early diagnosis is difficult and mainly depends on pathological and immunohistochemical examinations, and radical prostatectomy can be considered for its treatment.</p>


Subject(s)
Aged, 80 and over , Humans , Male , Adenocarcinoma, Mucinous , Pathology , Biopsy , Prostatic Neoplasms , Pathology
3.
National Journal of Andrology ; (12): 918-922, 2011.
Article in Chinese | WPRIM | ID: wpr-305763

ABSTRACT

<p><b>OBJECTIVE</b>To investigate the clinical presentations and pathologic features of undifferentiated sarcoma of the prostate with cartilage metaplasia, and to clarify its category.</p><p><b>METHODS</b>We analyzed the clinical data of a case of undifferentiated sarcoma of the prostate with cartilage metaplasia treated by surgical resection. The tumor tissue was subjected to routine HE and immunohistochemical staining, its histological structure and immunohistochemical expression were observed under the light microscope, and relevant literature on its manifestations was reviewed.</p><p><b>RESULTS</b>The case was pathologically diagnosed as gray prostate tumor, with chondrosarcomatous and undifferentiated malignant mesenchymal components under the light microscope. Immunohistochemical staining revealed vimentin (+), local CD117 (+/-), SMA (-), Des (-), myoglobin (-), CD34 (-), CK7 (-), and CK8 (-). Tumor metastasis was found 2 months after the operation, and the patient died 4 months later.</p><p><b>CONCLUSION</b>Undifferentiated sarcoma of the prostate with cartilage metaplasia is a very rare and highly malignant aggressive tumor, which can be diagnosed by biopsy and immunohistochemistry.</p>


Subject(s)
Adult , Humans , Male , Cartilage , Pathology , Metaplasia , Prostate , Pathology , Prostatic Neoplasms , Diagnosis , Pathology , Sarcoma , Diagnosis , Pathology
SELECTION OF CITATIONS
SEARCH DETAIL